Redux Therapeutics

Redux Therapeutics is a private clinical-stage biotechnology company focused on acquiring and developing therapeutic assets, with an apparent emphasis on small-molecule medicines for weight management and metabolic disease. Publicly available information links Redux Therapeutics closely to Response Pharmaceuticals, which is described as a sister company and appears to be the primary operating vehicle for the lead asset RDX-002. RDX-002 is a small-molecule inhibitor of microsomal triglyceride transfer protein being evaluated in Phase 2 studies in obesity-related metabolic settings, including post-GLP-1 discontinuation and antipsychotic-associated weight gain. Patent records assigned to Redux Therapeutics suggest an intellectual-property position around formulations and compositions involving microsomal triglyceride transfer protein and apolipoprotein B secretion inhibitors. Overall, Redux appears to function as a therapeutic asset holding and development company within a broader affiliated cardiometabolic drug-development group.